RecruitingNCT06409845

Effectiveness and Tolerability of Eptinezumab

Effectiveness and Tolerability of Eptinezumab: a Prospective, Multicentric, Cohort Study

Sponsor

University of Florence

Enrollment

100 participants

Start Date

Mar 26, 2024

Study Type

OBSERVATIONAL

Conditions

Migraine with aura Migraine Chronic Migraine Migraine Without Aura

Summary

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of eptinezumab as preventive migraine treatment in a cohort of episodic or chronic migraine patients.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III);
Good compliance to study procedures;
Availability of headache diary at least of the preceding months before enrolment;
At least 8 monthly migraine days.

Exclusion Criteria5

Subjects with contraindications for use of eptinezumab;
Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments;
medical comorbidities that could interfere with study results;
Pregnancy and breastfeeding
Changes in preventive treatments in the month before the first administration of eptinezumab

Interested in this trial?

Get notified about updates and connect with the research team.